BMB-101
Phase 2Small molecule
BMB-101 is one of 61 small molecule programs targeting Prader-Willi syndrome. It is currently in Phase 2.
2
Indications
3
Total Trials
2
Active Trials
60
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
84 competitors in Epilepsy
#DrugCompanyPhaseTrials
1Keppra
UCBApproved
Tegretol
NovartisApproved
Vimpat
UCBApproved
Trileptal
NovartisApproved
Fycompa
CCatalyst Biosciences
Approved
Lexapro
AbbVieApproved
Diamox
TevaApproved
Briviact
UCBPhase 3
Dilantin
VViatris Specialty LLC
Approved
Ketalar
AAultman Health Foundation
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
ART1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BMB-101. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- BBright Minds Biosciences Pty Ltd